News Column

BIND Therapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference

July 30, 2014



CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BINDís President and CEO, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference in New York on Wednesday, August 13, 2014 at 10:55 a.m. ET.

Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com. The webcasts will be archived on the BIND Therapeutics website following the event for one week.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineeringģ platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BINDís lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. BINDís platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Womenís Hospital/Harvard Medical School of BINDís scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company's web site at www.bindtherapeutics.com.





Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com

or

Investors:

Stern Investor Relations

Paul Cox, 212-362-1200

paul@sternir.com

Source: BIND Therapeutics, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters